124 related articles for article (PubMed ID: 94850)
1. Lack of leukocyte migration inhibition by hepatitis B surface antigen in hepatocellular carcinoma patients.
Lee CS; Chang KJ; Chen DS; Lin TY
Zhonghua Min Guo Wei Sheng Wu Xue Za Zhi; 1979 Sep; 12(3):86-92. PubMed ID: 94850
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of leukocyte migration by tumor-associated antigen in soluble extracts of human hepatoma.
Lee C; Chen S; Lin T
Cancer Res; 1977 Mar; 37(3):918-21. PubMed ID: 189919
[TBL] [Abstract][Full Text] [Related]
3. Purification of soluble hepatocellular carcinoma extracts.
Lee CS; Chuang CY; Lin FY; Lin TY
Zhonghua Min Guo Wei Sheng Wu Xue Za Zhi; 1979 Sep; 12(3):81-5. PubMed ID: 232674
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis B surface antigen and alpha-1-fetoprotein in hepatoma. Reports of 157 cases.
Pongpipat D; Suvatte V; Plengvanit U; Chinapak O; Bunyaphisit S; Assateerawatts A
J Med Assoc Thai; 1983 Nov; 66(11):696-9. PubMed ID: 6200559
[No Abstract] [Full Text] [Related]
5. Distribution of five antigens in hepatocellular carcinoma.
Thung SN; Gerber MA; Sarno E; Popper H
Lab Invest; 1979 Aug; 41(2):101-5. PubMed ID: 88543
[TBL] [Abstract][Full Text] [Related]
6. Improvement of dendritic-based vaccine efficacy against hepatitis B virus-related hepatocellular carcinoma by two tumor-associated antigen gene-infected dendritic cells.
Yang JY; Cao DY; Xue Y; Yu ZC; Liu WC
Hum Immunol; 2010 Mar; 71(3):255-62. PubMed ID: 20036295
[TBL] [Abstract][Full Text] [Related]
7. Hepatocellular carcinoma. A study of 50 autopsy cases with detection of hepatitis B surface antigen in fixed tissues.
Perez-Barrios A; Colina-Ruizdelgado F; Gallego I; Martinez-Tello FJ
Pathol Res Pract; 1983 Mar; 176(2-4):131-44. PubMed ID: 6190153
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemistry of hepatocellular carcinoma associated with cirrhosis.
Espinoza CG; Pillarisetti SG; Azar HA
Ann Clin Lab Sci; 1984; 14(6):467-73. PubMed ID: 6210034
[TBL] [Abstract][Full Text] [Related]
9. HLA antigen in Chinese patients with hepatocellular carcinomas.
Chan SH; Simons MJ; Oon CJ
J Natl Cancer Inst; 1980 Jul; 65(1):21-3. PubMed ID: 6156260
[TBL] [Abstract][Full Text] [Related]
10. Clinical features of hepatocellular carcinoma seronegative for both HBsAg and anti-HCV antibody but positive for anti-HBc antibody in Japan.
Yano Y; Yamashita F; Sumie S; Ando E; Fukumori K; Kiyama M; Oyama T; Kuroki S; Kato O; Yamamoto H; Tanaka M; Sata M
Am J Gastroenterol; 2002 Jan; 97(1):156-61. PubMed ID: 11808941
[TBL] [Abstract][Full Text] [Related]
11. Leukocyte migration inhibition assay in hepatoma patients and normal individuals: correlations with skin test.
Lee CS; Jan YY; Lin TY
Taiwan Yi Xue Hui Za Zhi; 1978 Sep; 77(9):661-5. PubMed ID: 214516
[No Abstract] [Full Text] [Related]
12. Soluble human leukocyte antigen-G expression in hepatitis B virus infection and hepatocellular carcinoma.
Park Y; Park Y; Lim HS; Kim YS; Hong DJ; Kim HS
Tissue Antigens; 2012 Feb; 79(2):97-103. PubMed ID: 22136460
[TBL] [Abstract][Full Text] [Related]
13. [Studies of an assay system for dialyzable leukocyte extracts (DLE)--influence of DLE on leukocyte migration inhibition test by HBsAg].
Hashimoto Y; Sekiguchi S
Hokkaido Igaku Zasshi; 1985 Sep; 60(5):763-8. PubMed ID: 3908264
[TBL] [Abstract][Full Text] [Related]
14. Inducing oral immune regulation of hepatitis B virus envelope proteins suppresses the growth of hepatocellular carcinoma in mice.
Gotsman I; Alper R; Klein A; Rabbani E; Engelhardt D; Ilan Y
Cancer; 2002 Jan; 94(2):406-14. PubMed ID: 11900226
[TBL] [Abstract][Full Text] [Related]
15. Impacts of human leukocyte antigen DQ genetic polymorphisms and their interactions with hepatitis B virus mutations on the risks of viral persistence, liver cirrhosis, and hepatocellular carcinoma.
Ji X; Zhang Q; Li B; Du Y; Yin J; Liu W; Zhang H; Cao G
Infect Genet Evol; 2014 Dec; 28():201-9. PubMed ID: 25281206
[TBL] [Abstract][Full Text] [Related]
16. Different expression of hepatitis B surface antigen between hepatocellular carcinoma and its surrounding liver tissue, studied using a tissue microarray.
Wang Y; Wu MC; Sham JS; Tai LS; Fang Y; Wu WQ; Xie D; Guan XY
J Pathol; 2002 Aug; 197(5):610-6. PubMed ID: 12210080
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis B surface antigen containing immune complexes occur in seronegative hepatocellular carcinoma patients.
Brown SE; Howard CR; Steward MW; Ajdukiewicz AB; Whittle HC
Clin Exp Immunol; 1984 Feb; 55(2):355-9. PubMed ID: 6199140
[TBL] [Abstract][Full Text] [Related]
18. HBsAg-negative hepatitis B virus infections in hepatitis C virus-associated hepatocellular carcinoma.
Momosaki S; Nakashima Y; Kojiro M; Tabor E
J Viral Hepat; 2005 May; 12(3):325-9. PubMed ID: 15850475
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis B viral markers in patients with primary hepatocellular carcinoma in Taiwan.
Chien MC; Tong MJ; Lo KJ; Lee JK; Milich DR; Vyas GN; Murphy BL
J Natl Cancer Inst; 1981 Mar; 66(3):475-9. PubMed ID: 6162990
[TBL] [Abstract][Full Text] [Related]
20. Presence of antibodies to the hepatitis B surface antigen is associated with an excess risk for hepatocellular carcinoma among non-Asians in Los Angeles County, California.
Yu MC; Yuan JM; Ross RK; Govindarajan S
Hepatology; 1997 Jan; 25(1):226-8. PubMed ID: 8985295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
